zimlovisertib (PF-06650833) / Pfizer 
Welcome,         Profile    Billing    Logout  
 0 Diseases   4 Trials   4 Trials   53 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zimlovisertib (PF-06650833) / Pfizer
PNA-COV, NCT04933799: IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

Recruiting
2
68
US
PF-06650833, IRAK 4 inhibitor, Matching Placebo, Placebo
Giovanni Franchin, M.D, Ph.D, Pfizer
COVID-19 Pneumonia
03/22
05/22
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zimlovisertib (PF-06650833) / Pfizer
PNA-COV, NCT04933799: IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

Recruiting
2
68
US
PF-06650833, IRAK 4 inhibitor, Matching Placebo, Placebo
Giovanni Franchin, M.D, Ph.D, Pfizer
COVID-19 Pneumonia
03/22
05/22

Download Options